Eyeing their first approval, BridgeBio sends their first drug to the FDA and lands a speedy review
Over the last five years, BridgeBio has raised about $1 billion, assembled over 20 different companies, extended networks into China and Israel and scored partnerships with a handful of top academic centers. Now, for the first time, they’ll have a drug before the FDA.
BridgeBio announced today that the FDA has accepted and handed priority review for fosdenopterin, an experimental medicine for a rare, irreversible neurological condition that appears in children and infants. Picked up two years ago from Alexion, it was the lead molecule for Origin Biosciences — a company they built specifically for the sake of bringing it through late-stage trials.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.